On Monday the Supreme Court in Washington will hear arguments in a case that could wipe out tens of thousands of lawsuits accusing Bayer’s Roundup of causing non‑Hodgkin lymphoma. The herbicide, introduced by Monsanto in the 1970s and acquired by Bayer in 2018, has become a flashpoint in U.S. toxic‑pesticide litigation. The Trump administration has formally sided with Bayer, reversing the previous federal stance today.

Bayer recently offered a $7.25 billion class‑action settlement in 2026, hoping to end the bulk of its Roundup litigation. The company argues that the EPA’s determination that glyphosate does not require a cancer warning pre‑empts state‑law failure‑to‑warn claims, a position echoed by the Justice Department. Environmental groups contend the EPA review is flawed and that state courts should retain the ability to hear claims.

If the Court affirms Bayer’s pre‑emption theory, the company could close a substantial portion of its liability, easing pressure on its balance sheet and stabilizing its share price, which has swung on litigation news. Farmers would retain access to the world’s most widely used glyphosate product, preserving current planting practices across roughly 300 million acres of U.S. cropland for years.